Claims for Patent: 10,155,808

Summary for Patent: 10,155,808

Title:	Monoclonal antibody against human PrPc and use thereof
Abstract:	A monoclonal antibody against human PrPc protein capable of reducing the expression level of transcription factor Twist1 in a targeting mode and inducing macrophage and NK cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone.
Inventor(s):	Chen; Quan (Beijing, CN), Li; Baowei (Beijing, CN), Hang; Haiying (Beijing, CN), Du; Lei (Beijing, CN), Wang; Jun (Beijing, CN), Wang; Xiaohui (Beijing, CN)
Assignee:	Institute of Zoology, Chinese Academy of Sciences (Beijing, CN)
Application Number:	15/351,418
Patent Claims:	1. A monoclonal Ab-5 antibody, which specifically binds to human cellular prion protein (PrPc). 2. A kit for detecting PrPc protein comprising the monoclonal Ab-5 antibody of claim 1. 3. The monoclonal Ab-5 antibody of claim 1, having a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:1, and a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:2. 4. An active fragment of the antibody of claim 3, wherein the active fragment comprises: a single chain antibody, an antibody Fab region, or an antigen-binding fragment. 5. A kit for detecting PrPc protein comprising the active fragment of claim 4. 6. An antitumor drug, comprising the monoclonal Ab-5 antibody of claim 1. 7. A synergistic adjuvant for an antitumor drug, comprising the monoclonal Ab-5 antibody of claim 1. 8. The synergistic adjuvant of claim 7, wherein the antitumor drug is cetuximab.

Details for Patent 10,155,808

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2034-05-15
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2034-05-15